Brian Rothman

Brian Rothman

Auto-generated profile, based on publicly available information

Brian Rothman

Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Dr, Princeton, NJ 08540, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Journal of Affective Disorders
Verified
Journal Article
Open access
BRBrian Rothman
Brian Rothman
MSMary Slomkowski
Mary Slomkowski
ASAustin Speier
Austin Speier
ARA. John Rush
A. John Rush
MTMadhukar Trivedi
Madhukar Trivedi
AFAinslie Forbes
Ainslie Forbes
Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This study evaluated the effectiveness and safety of a novel DTx, CT-152 (Rejoyn™), for MDD adjunctive to antidepressant medication monotherapy. Adults aged 22-64 years with MDD having an inadequate response to current antidepressant medication monotherapy were enrolled in a phase 3 multicenter, randomized, blinded, sham-controlled, remote trial with a 6-week intervention and 4-week extension. Delivered via smartphone apps, the CT-152 group received a cognitive-emotional and behavioral therapeutic intervention; the control group received a sham app with a working memory task. Both groups received supportive text messages and continued current antidepressant medication. The primary outcome was Montgomery-Åsberg Depression Rating Scale (MADRS) score change from baseline to week 6. Treatment-emergent adverse events (TEAEs) were assessed. Overall, 386 participants were randomly assigned (CT-152, n = 194; sham, n = 192). In the primary efficacy analysis of participants with ≥ 1 treatment session and ≥ 1 MADRS assessment post-baseline (n = 354), MADRS score changed -9.03 in the CT-152 group and - 7.25 in the sham (difference, - 1.78; P = 0.0568). These results were consistent with data from additional patient and clinician scales. In a supportive analysis of the intent-to-treat sample (N = 386), the between-group difference in 6-week MADRS change from baseline was -2.12 (P = 0.0211), favoring CT-152. No TEAEs or discontinuations were considered related to CT-152, and no deaths occurred. CT-152 resulted in depression symptom improvement and a favorable safety profile. Based on these data, CT-152 became the first FDA-authorized prescription DTx for the adjunctive treatment of MDD.

20 August 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
BRBrian Rothman
Brian Rothman
MSMary Slomkowski
Mary Slomkowski
ASAustin Speier
Austin Speier
ARA John Rush
A John Rush
MTMadhukar Trivedi
Madhukar Trivedi
AFAinslie Forbes
Ainslie Forbes
Background: Major depressive disorder (MDD) is common worldwide and can be highly disabling. People with MDD face many barriers to treatment and may not experience full symptom relief even when treated. Therefore, new treatment modalities are needed for MDD. Digital therapeutics (DTx) may provide people with MDD an additional treatment option. Objective: This study aimed to describe a phase 3 remote, multicenter, randomized, masked, sham-controlled trial evaluating the efficacy of a smartphone app–based DTx (CT-152) in adult participants diagnosed with MDD, used as an adjunct to antidepressant therapy (ADT). Methods: Participants aged 22-64 years with a current primary diagnosis of MDD and an inadequate response to ADT were included. Participants were randomized 1:1 to CT-152 or a sham DTx. CT-152 is a smartphone app–based DTx that delivers a cognitive-emotional and behavioral therapeutic intervention. The core components of CT-152 are the Emotional Faces Memory Task exercises, brief lessons to learn and apply key therapeutic skills, and SMS text messaging to reinforce lessons and encourage engagement with the app. The sham DTx is a digital working memory exercise with emotionally neutral stimuli designed to match CT-152 for time and attention. Participants took part in the trial for up to 13 weeks. The trial included a screening period of up to 3 weeks, a treatment period of 6 weeks, and an extension period of 4 weeks to assess the durability of the effect. Sites and participants had the option of an in-person or remote screening visit; the remaining trial visits were remote. Efficacy was evaluated using the Montgomery-Åsberg Depression Rating Scale, the Generalized Anxiety Disorder-7, Clinical Global Impression–Severity scale, the Patient Health Questionnaire-9, and the World Health Organization Disability Assessment Schedule 2.0. The durability of the effect was evaluated with the Montgomery-Åsberg Depression Rating Scale and Generalized Anxiety Disorder-7 scale. Adverse events were also assessed. Satisfaction, measured by the Participant and Healthcare Professional Satisfaction Scales, and health status, measured by the EQ-5D-5L, were summarized using descriptive statistics. Results: This study was initiated in February 2021 and had a primary completion date in October 2022. Conclusions: This represents the methodological design for the first evaluation of CT-152 as an adjunct to ADT. This study protocol is methodologically robust and incorporates many aspects of conventional pivotal pharmaceutical phase 3 trial design, such as randomization and safety end points. Novel considerations included the use of a sham comparator, masking considerations for visible app content, and outcome measures relevant to DTx. The rigor of this methodology will provide a more comprehensive understanding of the effectiveness of CT-152. Trial Registration: ClinicalTrials.gov NCT04770285; https://clinicaltrials.gov/study/NCT04770285 International Registered Report Identifier (IRRID): RR1-10.2196/56960

1 December 2018 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
RFR E Freundlich
R E Freundlich
JWJ P Walco
J P Walco
DMD M Mueller
D M Mueller
JWJ P Wanderer
J P Wanderer
BRB S Rothman
B S Rothman
LWL M Weavind
L M Weavind

19 November 2024 in Acta Neuropsychiatrica
Verified
Journal Article
Open access
PDF file
BRBrian Rothman
Brian Rothman
CBClaudette Brewer
Claudette Brewer
DCDenise Chang
Denise Chang
MHMary Hobart
Mary Hobart
NHNanco Hefting
Nanco Hefting
JGJon E. Grant
Jon E. Grant
Objective: No drugs are currently approved for the treatment of borderline personality disorder (BPD). These studies (a randomised study and its open-label extension) aimed to evaluate the efficacy, safety and tolerability of brexpiprazole for the treatment of BPD. Methods: The Phase 2, multicentre, randomised, double-blind, placebo-controlled, parallel-group study enrolled adult outpatients with BPD. After a 1-week placebo run-in, patients were randomised 1:1 to brexpiprazole 2–3 mg/day (flexible dose) or placebo for 11 weeks. The primary endpoint was change in Zanarini Rating Scale for BPD total score from randomisation (Week 1) to Week 10 (timing of randomisation and endpoint blinded to investigators and patients). The Phase 2/3, multicentre, open-label extension study enrolled patients who completed the randomised study; all patients received brexpiprazole 2–3 mg/day (flexible dose) for 12 weeks. Safety assessments included treatment-emergent adverse events (TEAEs). Results: Brexpiprazole was not statistically significantly different from placebo on the primary endpoint of the randomised study (N = 324 randomised; N = 110 analysed per treatment group; least squares mean difference −1.02; 95% confidence limits −2.75, 0.70; p = 0.24). Numerical efficacy advantages for brexpiprazole were observed at other time points. The most common TEAE in the randomised study was akathisia (brexpiprazole, 14.0%; placebo, 1.2%); data from the open-label study (N = 199 analysed) suggested that TEAEs were transient. Conclusion: The primary endpoint of the randomised study was not met. Further research on brexpiprazole in BPD is warranted based on possible efficacy signals at other time points and its safety profile. ClinicalTrials.gov identifiers: NCT04100096, NCT04186403. Funding: Otsuka, Lundbeck.

1 February 2024 in JMIR Preprints
Verified
Preprint
Open access
BRBrian Rothman
Brian Rothman
MSMary Slomkowski
Mary Slomkowski
ASAustin Speier
Austin Speier
ARA John Rush
A John Rush
MTMadhukar Trivedi
Madhukar Trivedi
AFAinslie Forbes
Ainslie Forbes
BACKGROUND Major depressive disorder (MDD) is common worldwide and can be highly disabling. People with MDD face many barriers to treatment and may not experience full symptom relief even when treated. Therefore, new treatment modalities are needed for MDD. Digital therapeutics (DTx) may provide people with MDD an additional treatment option. OBJECTIVE This study aimed to describe a phase 3 remote, multicenter, randomized, masked, sham-controlled trial evaluating the efficacy of a smartphone app–based DTx (CT-152) in adult participants diagnosed with MDD, used as an adjunct to antidepressant therapy (ADT). METHODS Participants aged 22-64 years with a current primary diagnosis of MDD and an inadequate response to ADT were included. Participants were randomized 1:1 to CT-152 or a sham DTx. CT-152 is a smartphone app–based DTx that delivers a cognitive-emotional and behavioral therapeutic intervention. The core components of CT-152 are the Emotional Faces Memory Task exercises, brief lessons to learn and apply key therapeutic skills, and SMS text messaging to reinforce lessons and encourage engagement with the app. The sham DTx is a digital working memory exercise with emotionally neutral stimuli designed to match CT-152 for time and attention. Participants took part in the trial for up to 13 weeks. The trial included a screening period of up to 3 weeks, a treatment period of 6 weeks, and an extension period of 4 weeks to assess the durability of the effect. Sites and participants had the option of an in-person or remote screening visit; the remaining trial visits were remote. Efficacy was evaluated using the Montgomery-Åsberg Depression Rating Scale, the Generalized Anxiety Disorder-7, Clinical Global Impression–Severity scale, the Patient Health Questionnaire-9, and the World Health Organization Disability Assessment Schedule 2.0. The durability of the effect was evaluated with the Montgomery-Åsberg Depression Rating Scale and Generalized Anxiety Disorder-7 scale. Adverse events were also assessed. Satisfaction, measured by the Participant and Healthcare Professional Satisfaction Scales, and health status, measured by the EQ-5D-5L, were summarized using descriptive statistics. RESULTS This study was initiated in February 2021 and had a primary completion date in October 2022. CONCLUSIONS This represents the methodological design for the first evaluation of CT-152 as an adjunct to ADT. This study protocol is methodologically robust and incorporates many aspects of conventional pivotal pharmaceutical phase 3 trial design, such as randomization and safety end points. Novel considerations included the use of a sham comparator, masking considerations for visible app content, and outcome measures relevant to DTx. The rigor of this methodology will provide a more comprehensive understanding of the effectiveness of CT-152. CLINICALTRIAL ClinicalTrials.gov NCT04770285; https://clinicaltrials.gov/study/NCT04770285 INTERNATIONAL REGISTERED REPORT RR1-10.2196/56960

21 September 2026 in JMIR Formative Research
Verified
Journal Article
Open access
SHStacie Hudgens
Stacie Hudgens
IPIntan Purnajo
Intan Purnajo
LFLysbeth Floden
Lysbeth Floden
SHSteve Hwang
Steve Hwang
JAJessica Ash
Jessica Ash
AFAinslie Forbes
Ainslie Forbes
Background: Rejoyn (CT-152) is a prescription digital therapeutic (DTx) adjunct to antidepressive medication authorized for patients with major depressive disorder. To better understand the patient benefit of DTx and other treatment modalities, current regulatory standards support the use of modern psychometric methods to interpret the clinical meaningfulness of treatment effects for patients. In the primary analysis of Rejoyn from the pivotal phase 3 Mirai trial (NCT04770285), Rejoyn showed a broad risk-to-benefit profile as demonstrated on multiple clinician- and patient-rated scales, including the primary efficacy outcome measure, the Montgomery-Åsberg Depression Rating Scale (MADRS). These findings supported US Food and Drug Administration authorization of Rejoyn as a prescription DTx. However, the clinical relevance of these changes in the MADRS score is not immediately interpretable in clinical practice. Here, we present the results from several post hoc analyses of the Mirai trial data to support the interpretation of clinically meaningful treatment differences on clinician- and patient-reported change in depressive symptoms. Objective: This study had two main objectives: (1) establish threshold parameters that allow for clinically meaningful interpretation of the Mirai results in clinical practice, based on the clinical trial end points of change from baseline in depressive symptoms, and (2) apply this threshold in a responder and sensitivity analysis in the intent-to-treat (ITT) population (which is more frequently reported in pharmacological trials) to further support the interpretation of change in unblinded analysis of the Mirai results. Methods: For the Mirai meaningful within-patient change (MWPC) analysis, anchor-based methods were used to define an MWPC threshold by exploring the associations between the MADRS and the clinician-rated Clinical Global Impression-Severity Scale (CGI-S) and the patient-reported Patient Health Questionnaire 9-Item Scale (PHQ-9). Additional post hoc efficacy analyses (including that of responders) are reported for the ITT population. Results: Using the MWPC thresholds of 8 and 10 points (derived with the CGI-S and PHQ-9 as anchor measures, respectively), the distribution of MADRS responders favored the Rejoyn group over the sham group, and the Rejoyn group had 24%‐47% higher odds of meaningful improvement on the MADRS. Post hoc ITT analyses also favored the Rejoyn group over the sham group for response rates and PHQ-9 and CGI-S score change from baseline. Conclusions: Results are consistent with the primary findings of the Mirai trial, supporting the efficacy of Rejoyn as an adjunctive treatment to antidepressive medication monotherapy for adults with major depressive disorder. The MWPC analyses offered a measure of meaningful change on the MADRS, providing a framework of clinical meaningfulness for the Mirai trial findings.